Hans BrÃ¤uner-Osborne

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2153045/publications.pdf

Version: 2024-02-01

221	10,226	36303	48315
papers	citations	51 h-index	88 g-index

226	226	226	11160
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ligand-directed bias of G protein signaling at the dopamine D2 receptor. Cell Chemical Biology, 2022, 29, 226-238.e4.	5.2	14
2	Somatostatin venom analogs evolved by fish-hunting cone snails: From prey capture behavior to identifying drug leads. Science Advances, 2022, 8, eabk1410.	10.3	12
3	Molecular insights into ligand recognition and G protein coupling of the neuromodulatory orphan receptor GPR139. Cell Research, 2022, 32, 210-213.	12.0	13
4	Delineation of the GPR15 receptorâ€mediated GÎ± protein signalling profile in recombinant mammalian cells. Basic and Clinical Pharmacology and Toxicology, 2022, 131, 104-113.	2.5	4
5	The Calcium-Sensing Receptor Is Essential for Calcium and Bicarbonate Sensitivity in Human Spermatozoa. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1775-1792.	3.6	12
6	Arrestin-Dependent and -Independent Internalization of G Proteinâ€“Coupled Receptors: Methods, Mechanisms, and Implications on Cell Signaling. Molecular Pharmacology, 2021, 99, 242-255.	2.3	41
7	Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Tool Compounds to Study Signaling Bias. Molecular Pharmacology, 2021, 99, 328-341.	2.3	5
8	Asymmetric activation of the calcium-sensing receptor homodimer. Nature, 2021, 595, 455-459.	27.8	59
9	Mutational Landscape of the Proglucagon-Derived Peptides. Frontiers in Endocrinology, 2021, 12, 698511.	3.5	7
10	Metabotropic glutamate receptors in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	0
11	Calcium-sensing receptor in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	0
12	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G proteinâ€coupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.	5.4	337
13	GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats. ACS Pharmacology and Translational Science, 2021, 4, 296-313.	4.9	24
14	Pharmacology and function of the orphan GPR139 G proteinâ€coupled receptor. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 35-46.	2.5	17
15	G proteinâ€coupled receptor pharmacologyâ€”The next generation. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 3-4.	2.5	2
16	Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and longâ€term impairment of the GIP system. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 122-132.	2.5	27
17	Biased agonism of clinically approved Î¼-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics. Neuropharmacology, 2020, 166, 107718.	4.1	61
18	Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1). Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1322-e1330.	3.6	4

#	Article	IF	Citations
19	Novel approaches leading towards peptide GPCR deâ€orphanisation. British Journal of Pharmacology, 2020, 177, 961-968.	5.4	30
20	Dissecting the roles of GRK2 and GRK3 in Î¼-opioid receptor internalization and Î²-arrestin2 recruitment using CRISPR/Cas9-edited HEK293 cells. Scientific Reports, 2020, 10, 17395.	3.3	33
21	Pharmacology and physiological function of the orphan GPRC6A receptor. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 77-87.	2.5	19
22	Delineation of molecular determinants for FR900359 inhibition of Gq/11 unlocks inhibition of GÎ±s. Journal of Biological Chemistry, 2020, 295, 13850-13861.	3.4	11
23	Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5. Molecular Pharmacology, 2020, 98, 49-60.	2.3	12
24	International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function. Pharmacological Reviews, 2020, 72, 558-604.	16.0	59
25	The selective 5-HT2A receptor agonist 25CN-NBOH: Structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [3H]25CN-NBOH. Biochemical Pharmacology, 2020, 177, 113979.	4.4	15
26	Calcium-sensing receptor (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2020, 2020, .	0.2	0
27	Probing the Existence of a Metastable Binding Site at the Î²₂-Adrenergic Receptor with Homobivalent Bitopic Ligands. Journal of Medicinal Chemistry, 2019, 62, 7806-7839.	6.4	9
28	Discovery of Human Signaling Systems: Pairing Peptides to G Protein-Coupled Receptors. Cell, 2019, 179, 895-908.e21.	28.9	157
29	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G proteinâ€coupled receptors. British Journal of Pharmacology, 2019, 176, S21-S141.	5.4	519
30	Metabolic and skeletal homeostasis are maintained in full locus GPRC6A knockout mice. Scientific Reports, 2019, 9, 5995.	3.3	17
31	Identification of a novel scaffold for a small molecule GPR139 receptor agonist. Scientific Reports, 2019, 9, 3802.	3.3	10
32	Label-free dynamic mass redistribution analysis of endogenous adrenergic receptor signaling in primary preadipocytes and differentiated adipocytes. Journal of Pharmacological and Toxicological Methods, 2019, 97, 59-66.	0.7	2
33	Structureâ€“Activity Relationship Studies of the Natural Product G_{q/11} Protein Inhibitor YMâ€254890. ChemMedChem, 2019, 14, 865-870.	3.2	21
34	Rational design of a heterotrimeric G protein Î± subunit with artificial inhibitor sensitivity. Journal of Biological Chemistry, 2019, 294, 5747-5758.	3.4	32
35	Calcium-Sensing Receptor Internalization IsÎ²-Arrestinâ€“Dependent and Modulated by Allosteric Ligands. Molecular Pharmacology, 2019, 96, 463-474.	2.3	23
36	Calcium-sensing receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	2

#	Article	IF	Citations
37	Class C Orphans (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	2
38	Metabotropic glutamate receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	1
39	Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors. Biochemical Pharmacology, 2018, 150, 97-107.	4.4	65
40	Structureâ€“activity relationship and conformational studies of the natural product cyclic depsipeptides YM-254890 and FR900359. European Journal of Medicinal Chemistry, 2018, 156, 847-860.	5.5	24
41	Structural insight to mutation effects uncover a common allosteric site in class C GPCRs. Bioinformatics, 2017, 33, 1116-1120.	4.1	9
42	Genetic Variations in the Human G Protein-coupled Receptor Class C, Group 6, Member A (GPRC6A) Control Cell Surface Expression and Function. Journal of Biological Chemistry, 2017, 292, 1524-1534.	3.4	23
43	The orphan G protein-coupled receptor GPR139 is activated by the peptides: Adrenocorticotropic hormone (ACTH), Î±-, and Î²-melanocyte stimulating hormone (Î±-MSH, and Î²-MSH), and the conserved core motif HFRW. Neurochemistry International, 2017, 102, 105-113.	3.8	36
44	Investigating the molecular mechanism of positive and negative allosteric modulators in the calcium-sensing receptor dimer. Scientific Reports, 2017, 7, 46355.	3.3	25
45	Structureâ€“Activity Relationship Studies of the Cyclic Depsipeptide Natural Product YMâ€254890, Targeting the G_q Protein. ChemMedChem, 2017, 12, 830-834.	3.2	23
46	Identification of AICP as a GluN2C-Selective N-Methyl-d-Aspartate Receptor Superagonist at the GluN1 Glycine Site. Molecular Pharmacology, 2017, 92, 151-161.	2.3	16
47	Detailed Characterization of the In Vitro Pharmacological and Pharmacokinetic Properties ofN-(2-Hydroxybenzyl)-2,5-Dimethoxy-4-Cyanophenylethylamine (25CN-NBOH), a Highly Selective and Brain-Penetrant 5-HT_{2A}Receptor Agonist. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 441-453.	2.5	45
48	The GPRC6A receptor displays constitutive internalization and sorting to the slow recycling pathway. Journal of Biological Chemistry, 2017, 292, 6910-6926.	3.4	30
49	Robust <scp>GLP</scp>â€1 secretion by basic <scp>L</scp>â€amino acids does not require the <scp>GPRC6A</scp> receptor. Diabetes, Obesity and Metabolism, 2017, 19, 599-603.	4.4	28
50	Structureâ€“Activity Relationship, Pharmacological Characterization, and Molecular Modeling of Noncompetitive Inhibitors of the Betaine/Î³-Aminobutyric Acid Transporter 1 (BGT1). Journal of Medicinal Chemistry, 2017, 60, 8834-8846.	6.4	16
51	Investigating Internalization and Intracellular Trafficking of GPCRs: New Techniques and Real-Time Experimental Approaches. Handbook of Experimental Pharmacology, 2017, 245, 41-61.	1.8	29
52	The GPR139 reference agonists 1a and 7c, and tryptophan and phenylalanine share a common binding site. Scientific Reports, 2017, 7, 1128.	3.3	25
53	Applying label-free dynamic mass redistribution assay for studying endogenous FPR1 receptor signalling in human neutrophils. Journal of Pharmacological and Toxicological Methods, 2017, 88, 72-78.	0.7	11
54	Identification of Histamine H3 Receptor Ligands Using a New Crystal Structure Fragment-based Method. Scientific Reports, 2017, 7, 4829.	3.3	10

#	Article	IF	Citations
55	Knockin mouse with mutant GÎ±11 mimics human inherited hypocalcemia and is rescued by pharmacologic inhibitors. JCI Insight, 2017, 2, e91079.	5.0	26
56	Total synthesis and structureâ€“activity relationship studies of a series of selective G protein inhibitors. Nature Chemistry, 2016, 8, 1035-1041.	13.6	67
57	Novel Agonist Bioisosteres and Common Structure-Activity Relationships for The Orphan G Protein-Coupled Receptor GPR139. Scientific Reports, 2016, 6, 36681.	3.3	23
58	Radiosynthesis and characterisation of a potent and selective GPR139 agonist radioligand. RSC Advances, 2016, 6, 947-952.	3.6	8
59	The Concise Guide to PHARMACOLOGY 2015/16: Overview. British Journal of Pharmacology, 2015, 172, 5729-5743.	5.4	220
60	Selective Negative Allosteric Modulation Of Metabotropic Glutamate Receptors â€“ A Structural Perspective of Ligands and Mutants. Scientific Reports, 2015, 5, 13869.	3.3	38
61	Nâ€glycosylation and disulfide bonding affects GPRC6A receptor expression, function, and dimerization. FEBS Letters, 2015, 589, 588-597.	2.8	29
62	Functional Consequences of Glucagon-like Peptide-1 Receptor Cross-talk and Trafficking. Journal of Biological Chemistry, 2015, 290, 1233-1243.	3.4	63
63	Identification of the first surrogate agonists for the G protein-coupled receptor GPR132. RSC Advances, 2015, 5, 48551-48557.	3.6	8
64	Role of post-translational modifications on structure, function and pharmacology of class C G protein-coupled receptors. European Journal of Pharmacology, 2015, 763, 233-240.	3.5	29
65	A cAMP Biosensor-Based High-Throughput Screening Assay for Identification of Gs-Coupled GPCR Ligands and Phosphodiesterase Inhibitors. Journal of Biomolecular Screening, 2015, 20, 849-857.	2.6	21
66	Selective Allosteric Antagonists for the G Protein-Coupled Receptor GPRC6A Based on the 2-Phenylindole Privileged Structure Scaffold. Journal of Medicinal Chemistry, 2015, 58, 8938-8951.	6.4	22
67	Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists. Bioorganic and Medicinal Chemistry, 2015, 23, 3933-3937.	3.0	25
68	Introduction to Special Issue in Honor of Professor Povl Krogsgaard-Larsen. Neurochemical Research, 2014, 39, 1845-1846.	3.3	0
69	G Protein-Coupled Receptor Signaling Analysis Using Homogenous Time-Resolved FÃ¶rster Resonance Energy Transfer (HTRFÂ®) Technology. International Journal of Molecular Sciences, 2014, 15, 2554-2572.	4.1	39
70	The <scp>GPCR</scp>, class <scp>C</scp>, group 6, subtype <scp>A</scp> (<scp>GPRC6A</scp>) receptor: from cloning to physiological function. British Journal of Pharmacology, 2014, 171, 1129-1141.	5.4	87
71	Real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Molecular and Cellular Endocrinology, 2014, 382, 938-949.	3.2	131
72	mGluR5: Exploration of Orthosteric and Allosteric Ligand Binding Pockets and Their Applications to Drug Discovery. Neurochemical Research, 2014, 39, 1862-1875.	3.3	29

#	Article	IF	Citations
73	Synthesis and Structureâ€“Activity Relationships of N-Benzyl Phenethylamines as 5-HT_{2A/2C} Agonists. ACS Chemical Neuroscience, 2014, 5, 243-249.	3.5	103
74	Computer-Aided Discovery of Aromatic <scp>l</scp>-Î±-Amino Acids as Agonists of the Orphan G Protein-Coupled Receptor GPR139. Journal of Chemical Information and Modeling, 2014, 54, 1553-1557.	5.4	50
75	Pharmacological Identification of a Guanidine-Containing Î²-Alanine Analogue with Low Micromolar Potency and Selectivity for the Betaine/GABA Transporter 1 (BGT1). Neurochemical Research, 2014, 39, 1988-1996.	3.3	20
76	Promiscuous Seven Transmembrane Receptors Sensing L-α-amino Acids. Current Pharmaceutical Design, 2014, 20, 2693-2702.	1.9	7
77	cAMP Biosensors Applied in Molecular Pharmacological Studies of G Protein-Coupled Receptors. Methods in Enzymology, 2013, 522, 191-207.	1.0	14
78	Oral l-Arginine Stimulates GLP-1 Secretion to Improve Glucose Tolerance in Male Mice. Endocrinology, 2013, 154, 3978-3983.	2.8	58
79	The l-Î±-amino acid receptor GPRC6A is expressed in the islets of Langerhans but is not involved in l-arginine-induced insulin release. Amino Acids, 2013, 44, 383-390.	2.7	46
80	Crystal Structure and Pharmacological Characterization of a Novel N-Methyl-d-aspartate (NMDA) Receptor Antagonist at the GluN1 Glycine Binding Site. Journal of Biological Chemistry, 2013, 288, 33124-33135.	3.4	22
81	Enhanced voluntary wheel running in GPRC6A receptor knockout mice. Physiology and Behavior, 2013, 118, 144-151.	2.1	16
82	3-Substituted 2-phenyl-indoles: privileged structures for medicinal chemistry. RSC Advances, 2013, 3, 945-960.	3.6	59
83	Discovery of a subtype selective inhibitor of the human betaine/GABA transporter 1 (BGT-1) with a non-competitive pharmacological profile. Biochemical Pharmacology, 2013, 86, 521-528.	4.4	29
84	Structure-based discovery of antagonists for GluN3-containing N-methyl-d-aspartate receptors. Neuropharmacology, 2013, 75, 324-336.	4.1	36
85	Delineation of the GPRC6A Receptor Signaling Pathways Using a Mammalian Cell Line Stably Expressing the Receptor. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 298-309.	2.5	61
86	Increased susceptibility to diet-induced obesity in GPRC6A receptor knockout mice. Journal of Endocrinology, 2013, 217, 151-160.	2.6	33
87	GABAB-Agonistic Activity of Certain Baclofen Homologues. Molecules, 2013, 18, 10266-10284.	3.8	10
88	The orthosteric <scp>GABA_A</scp> receptor ligand <scp>T</scp>hioâ€4â€<scp>PIOL</scp> displays distinctly different functional properties at synaptic and extrasynaptic receptors. British Journal of Pharmacology, 2013, 170, 919-932.	5.4	14
89	Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E310-E320.	3.5	89
90	Synthesis of the calcilytic ligand NPS 2143. Beilstein Journal of Organic Chemistry, 2013, 9, 1383-1387.	2.2	7

#	Article	IF	Citations
91	Î±4Î²2Î´ GABA _A receptors are high-affinity targets for Î³-hydroxybutyric acid (GHB). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13404-13409.	7.1	87
92	Pharmacological Characterization and Modeling of the Binding Sites of Novel 1,3-Bis(pyridinylethynyl)benzenes as Metabotropic Glutamate Receptor 5-Selective Negative Allosteric Modulators. Molecular Pharmacology, 2012, 82, 929-937.	2.3	34
93	Novel Strategies in Drug Discovery of the Calcium-Sensing Receptor Based on Biased Signaling. Current Drug Targets, 2012, 13, 1324-1335.	2.1	15
94	(1S, 3S)-3-Amino-4-difluoromethylenyl-1-cyclopentanoic Acid (CPP-115), a Potent Î³-Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Cocaine Addiction. Journal of Medicinal Chemistry, 2012, 55, 357-366.	6.4	43
95	Molecular pharmacology of human NMDA receptors. Neurochemistry International, 2012, 61, 601-609.	3.8	74
96	l-Arginine improves multiple physiological parameters in mice exposed to diet-induced metabolic disturbances. Amino Acids, 2012, 43, 1265-1275.	2.7	49
97	Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nature Communications, 2012, 3, 1329.	12.8	369
98	Strontium Is a Biased Agonist of the Calcium-Sensing Receptor in Rat Medullary Thyroid Carcinoma 6-23 Cells. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 638-649.	2.5	38
99	Structureâ€“Activity Relationships for Negative Allosteric mGluR5 Modulators. ChemMedChem, 2012, 7, 440-451.	3.2	19
100	Biased agonism of the calcium-sensing receptor. Cell Calcium, 2012, 51, 107-116.	2.4	76
101	A highly selective agonist for the metabotropic glutamate receptor mGluR2. MedChemComm, 2011, 2, 1120.	3.4	9
102	The use ofXenopusoocytes in drug screening. Expert Opinion on Drug Discovery, 2011, 6, 141-153.	5.0	23
103	Transmembrane Î±-Helix 2 and 7 Are Important for Small Molecule-Mediated Activation of the GLP-1 Receptor. Pharmacology, 2011, 88, 340-348.	2.2	9
104	Chemogenomic Discovery of Allosteric Antagonists at the GPRC6A Receptor. Chemistry and Biology, 2011, 18, 1489-1498.	6.0	36
105	Quinazolin-4-one Derivatives: A Novel Class of Noncompetitive NR2C/D Subunit-Selective N-Methyl-<scp>d</scp>-aspartate Receptor Antagonists. Journal of Medicinal Chemistry, 2010, 53, 5476-5490.	6.4	83
106	Homology Modelling of the GABA Transporter and Analysis of Tiagabine Binding. ChemMedChem, 2010, 5, 986-1000.	3.2	50
107	Novel 3â€Carboxyâ€and 3â€Phosphonopyrazoline Amino Acids as Potent and Selective NMDA Receptor Antagonists: Design, Synthesis, and Pharmacological Characterization. ChemMedChem, 2010, 5, 1465-1475.	3.2	22
108	A new metabotropic glutamate receptor agonist with in vivo anti-allodynic activity. Bioorganic and Medicinal Chemistry, 2010, 18, 6089-6098.	3.0	6

#	Article	IF	Citations
109	1,2,3-Triazolyl amino acids as AMPA receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7512-7515.	2.2	28
110	Novel Radioiodinated Î³-Hydroxybutyric Acid Analogues for Radiolabeling and Photolinking of High-Affinity Î³-Hydroxybutyric Acid Binding Sites. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 458-464.	2.5	16
111	Implementation of a Fluorescence-Based Screening Assay Identifies Histamine H3 Receptor Antagonists Clobenpropit and Iodophenpropit as Subunit-Selective N-Methyl-d-Aspartate Receptor Antagonists. Journal of Pharmacology and Experimental Therapeutics, 2010, 333, 650-662.	2.5	40
112	The Emerging Role of Promiscuous 7TM Receptors as Chemosensors for Food Intake. Vitamins and Hormones, 2010, 84, 151-184.	1.7	22
113	Design, Synthesis, and in Vitro Pharmacology of New Radiolabeled Î³-Hydroxybutyric Acid Analogues Including Photolabile Analogues with Irreversible Binding to the High-Affinity Î³-Hydroxybutyric Acid Binding Sites. Journal of Medicinal Chemistry, 2010, 53, 6506-6510.	6.4	20
114	(R)-(3-Amino-2-fluoropropyl) Phosphinic Acid (AZD3355), a Novel GABA_B Receptor Agonist, Inhibits Transient Lower Esophageal Sphincter Relaxation through a Peripheral Mode of Action. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 504-512.	2.5	49
115	No evidence for a bone phenotype in GPRC6A knockout mice under normal physiological conditions. Journal of Molecular Endocrinology, 2009, 42, 215-223.	2.5	63
116	The Four Human γ-Aminobutyric Acid (GABA) Transporters: Pharmacological Characterization and Validation of a Highly Efficient Screening Assay. Combinatorial Chemistry and High Throughput Screening, 2009, 12, 241-249.	1.1	38
117	Molecular determinants of non-competitive antagonist binding to the mouse GPRC6A receptor. Cell Calcium, 2009, 46, 323-332.	2.4	50
118	Molecular basis for amino acid sensing by family C Gâ€proteinâ€coupled receptors. British Journal of Pharmacology, 2009, 156, 869-884.	5.4	99
119	Phenylacetic acids and the structurally related nonâ€steroidal antiâ€inflammatory drug diclofenac bind to specific Î³â€hydroxybutyric acid sites in rat brain. Fundamental and Clinical Pharmacology, 2009, 23, 207-213.	1.9	19
120	FLIPRÂ® Assays of Intracellular Calcium in GPCR Drug Discovery. Methods in Molecular Biology, 2009, 552, 269-278.	0.9	23
121	The GABA_{B1a}Isoform Mediates Heterosynaptic Depression at Hippocampal Mossy Fiber Synapses. Journal of Neuroscience, 2009, 29, 1414-1423.	3.6	54
122	Molecular Pharmacology of Promiscuous Seven Transmembrane Receptors Sensing Organic Nutrients. Molecular Pharmacology, 2009, 76, 453-465.	2.3	140
123	The Glutamate Receptor GluR5 Agonist (S)-2-Amino-3-(3-hydroxy-7,8-dihydro-6H-cyclohepta[d]isoxazol-4-yl)propionic Acid and the 8-Methyl Analogue: Synthesis, Molecular Pharmacology, and Biostructural Characterizationâ€PDB ID: 2WKY.. Journal of Medicinal Chemistry, 2009, 52, 4911-4922.	6.4	21
124	Xenopus Oocyte Electrophysiology in GPCR Drug Discovery. Methods in Molecular Biology, 2009, 552, 343-357.	0.9	18
125	3B but which 3B? And that's just one of the questions: the heterogeneity of human 5-HT3 receptors. Trends in Pharmacological Sciences, 2008, 29, 437-444.	8.7	67
126	Novel High-Affinity and Selective Biaromatic 4-Substituted Î³-Hydroxybutyric Acid (GHB) Analogues as GHB Ligands: Design, Synthesis, and Binding Studies. Journal of Medicinal Chemistry, 2008, 51, 8088-8095.	6.4	26

#	Article	IF	Citations
127	N-Hydroxypyrazolyl Glycine Derivatives as Selective N-Methyl-d-aspartic Acid Receptor Ligands. Journal of Medicinal Chemistry, 2008, 51, 4179-4187.	6.4	19
128	Synthesis and Pharmacological Characterization at Glutamate Receptors of the Four Enantiopure Isomers of Tricholomic Acid. Journal of Medicinal Chemistry, 2008, 51, 2311-2315.	6.4	30
129	Pharmacological Characterization of Ligands at Recombinant NMDA Receptor Subtypes by Electrophysiological Recordings and Intracellular Calcium Measurements. Combinatorial Chemistry and High Throughput Screening, 2008, 11, 304-315.	1.1	31
130	High-frequency HTR3B variant associated with major depression dramatically augments the signaling of the human 5-HT _{3AB} receptor. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 722-727.	7.1	72
131	Characterization of the effects of four HTR3B polymorphisms on human 5-HT3AB receptor expression and signalling. Pharmacogenetics and Genomics, 2008, 18, 1027-1040.	1.5	8
132	Cloning and Characterization of a Functional Human Î³-Aminobutyric Acid (GABA) Transporter, Human GAT-2. Journal of Biological Chemistry, 2007, 282, 19331-19341.	3.4	44
133	Structure, Pharmacology and Therapeutic Prospects of Family C G-Protein Coupled Receptors. Current Drug Targets, 2007, 8, 169-184.	2.1	222
134	Allosteric Modulation of the Calcium-Sensing Receptor. Current Neuropharmacology, 2007, 5, 180-186.	2.9	51
135	Naturally occurring variations in the human 5-HT3A gene profoundly impact 5-HT3 receptor function and expression. Pharmacogenetics and Genomics, 2007, 17, 255-266.	1.5	35
136	The rat GPRC6A: Cloning and characterization. Gene, 2007, 396, 257-267.	2.2	46
137	Functional Characterization of Tet-AMPA [Tetrazolyl-2-amino-3-(3-hydroxy-5-methyl-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 35 Molecular Basis for the Functional Selectivity Profile of 2-Bn-Tet-AMPA. Journal of Medicinal Chemistry, 2007, 50, 4177-4185.	6.4	17
138	Synthesis of Conformationally Constrained Glutamic Acid Homologues and Investigation of Their Pharmacological Profiles. ChemMedChem, 2007, 2, 1639-1647.	3.2	14
139	Synthesis and pharmacological characterization at glutamate receptors of erythro- and threo-tricholomic acid and homologues thereof. Tetrahedron, 2007, 63, 2249-2256.	1.9	18
140	Novel 5-substituted 1-pyrazolol analogues of ibotenic acid: Synthesis and pharmacology at glutamate receptors. Bioorganic and Medicinal Chemistry, 2007, 15, 3524-3538.	3.0	15
141	Pharmacological characterization of mouse GPRC6A, an L -Î± -amino-acid receptor modulated by divalent cations. British Journal of Pharmacology, 2007, 150, 798-807.	5.4	74
142	Synthesis and pharmacology of glutamate receptor ligands: new isothiazole analogues of ibotenic acid. Organic and Biomolecular Chemistry, 2007, 5, 463-471.	2.8	21
143	Rational Design and Enantioselective Synthesis of (1R,4S,5R,6S)-3-Azabicyclo[3.3.0]octane-4,6-dicarboxylic Acid A Novel Inhibitor at Human Glutamate Transporter Subtypes 1, 2, and 3. Journal of Medicinal Chemistry, 2006, 49, 172-178.	6.4	22
144	Differential Compartmentalization and Distinct Functions of GABAB Receptor Variants. Neuron, 2006, 50, 589-601.	8.1	289

#	Article	IF	Citations
145	Known regulators of nitric oxide synthase and arginase are agonists at the human G-protein-coupled receptor GPRC6A. British Journal of Pharmacology, 2006, 147, 855-863.	5.4	22
146	Activity of l-Î±-amino acids at the promiscuous goldfish odorant receptor 5.24. European Journal of Pharmacology, 2006, 536, 98-101.	3.5	9
147	Functional Characterisation of Homomeric Ionotropic Glutamate Receptors GluR1-GluR6 in a Fluorescence-Based High Throughput Screening Assay. Combinatorial Chemistry and High Throughput Screening, 2006, 9, 147-158.	1.1	19
148	Tetrazolyl isoxazole amino acids as ionotropic glutamate receptor antagonists: Synthesis, modelling and molecular pharmacology. Bioorganic and Medicinal Chemistry, 2005, 13, 5391-5398.	3.0	9
149	Azetidinic amino acids: stereocontrolled synthesis and pharmacological characterization as ligands for glutamate receptors and transporters. Organic and Biomolecular Chemistry, 2005, 3, 3926.	2.8	50
150	Synthesis of NovelN1-Substituted Bicyclic Pyrazole Amino Acids and Evaluation of Their Interaction with Glutamate Receptors. Chemistry and Biodiversity, 2005, 2, 748-757.	2.1	3
151	Rigid nonproteinogenic cyclic amino acids as ligands for glutamate receptors:trans-Tris(homoglutamic) acids. Chirality, 2005, 17, 99-107.	2.6	4
152	Deorphanization of GPRC6A: A Promiscuous l-Î±-Amino Acid Receptor with Preference for Basic Amino Acids. Molecular Pharmacology, 2005, 67, 589-597.	2.3	194
153	Tweaking Agonist Efficacy at N-Methyl-d-aspartate Receptors by Site-Directed Mutagenesis. Molecular Pharmacology, 2005, 68, 1510-1523.	2.3	24
154	Novel Cyclic Î³-Hydroxybutyrate (GHB) Analogs with High Affinity and Stereoselectivity of Binding to GHB Sites in Rat Brain. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 346-351.	2.5	45
155	4-Alkylated homoibotenic acid (HIBO) analogues: Versatile pharmacological agents with diverse selectivity profiles towards metabotropic and ionotropic glutamate receptor subtypes. Neuropharmacology, 2005, 49, 114-119.	4.1	21
156	Chemoenzymatic Synthesis of a Series of 4-Substituted Glutamate Analogues and Pharmacological Characterization at Human Glutamate Transporters Subtypes 1â"3. Journal of Medicinal Chemistry, 2005, 48, 7980-7992.	6.4	35
157	Synthesis, Binding Affinity at Glutamic Acid Receptors, Neuroprotective Effects, and Molecular Modeling Investigation of Novel Dihydroisoxazole Amino Acids. Journal of Medicinal Chemistry, 2005, 48, 6315-6325.	6.4	43
158	GABA and Glutamate Receptor Ligands and Their Therapeutic Potential in CNS Disorders. , 2005, , 797-907.		3
159	Mutation-induced Quisqualic Acid and Ibotenic Acid Affinity at the Metabotropic Glutamate Receptor Subtype 4. Journal of Biological Chemistry, 2004, 279, 34811-34817.	3.4	16
160	Ibotenic acid and thioibotenic acid: a remarkable difference in activity at group III metabotropic glutamate receptors. European Journal of Pharmacology, 2004, 486, 241-250.	3.5	47
161	Carbamoylcholine homologs: synthesis and pharmacology at nicotinic acetylcholine receptors. European Journal of Pharmacology, 2004, 497, 125-137.	3.5	9
162	The respective N-hydroxypyrazole analogues of the classical glutamate receptor ligands ibotenic acid and (RS)-2-amino-2-(3-hydroxy-5-methyl-4-isoxazolyl)acetic acid. European Journal of Pharmacology, 2004, 499, 35-44.	3.5	23

#	Article	IF	Citations
163	Pharmacological characterization of human excitatory amino acid transporters EAAT1, EAAT2 and EAAT3 in a fluorescence-based membrane potential assay. Biochemical Pharmacology, 2004, 67, 2115-2127.	4.4	67
164	Synthesis, theoretical and structural analyses, and enantiopharmacology of 3-carboxy homologs of AMPA. Chirality, 2004, 16, 452-466.	2.6	6
165	Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-protein-coupled receptor. Gene, 2004, 335, 37-46.	2.2	147
166	Design, Synthesis, and Pharmacological Characterization of Novel, Potent NMDA Receptor Antagonists. Journal of Medicinal Chemistry, 2004, 47, 6740-6748.	6.4	22
167	The GABAB Receptor. , 2004, , 129-144.		3
168	Design of Cyclopentaisoxazoline Amino Acids as Conformationally Constrained Agonists at Glutamate Receptors. European Journal of Organic Chemistry, 2003, 2003, 4455-4461.	2.4	6
169	Design of novel conformationally restricted analogues of glutamic acid. Tetrahedron, 2003, 59, 1443-1452.	1.9	11
170	Different domains of the glucagon and glucagonâ€like peptideâ€1 receptors provide the critical determinants of ligand selectivity. British Journal of Pharmacology, 2003, 138, 787-794.	5.4	103
171	Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. British Journal of Pharmacology, 2003, 138, 1026-1030.	5.4	163
172	Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABAB(1)-deficient mice. European Journal of Neuroscience, 2003, 18, 2722-2730.	2.6	175
173	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. Bioorganic and Medicinal Chemistry, 2003, 11, 4341-4349.	3.0	12
174	(S)-2-Amino-3-(3-hydroxy-7,8-dihydro-6H-cyclohepta[d]isoxazol-4-yl)propionic Acid, a Potent and Selective Agonist at the GluR5 Subtype of Ionotropic Glutamate Receptors. Synthesis, Modeling, and Molecular Pharmacology. Journal of Medicinal Chemistry, 2003, 46, 1350-1358.	6.4	26
175	Carbamoylcholine Homologs: Novel and Potent Agonists at Neuronal Nicotinic Acetylcholine Receptors. Molecular Pharmacology, 2003, 64, 865-875.	2.3	52
176	Design, Synthesis, and Pharmacology of a Highly Subtype-Selective GluR1/2 Agonist, (RS)-2-Amino-3-(4-chloro-3-hydroxy-5-isoxazolyl)propionic Acid (Cl-HIBO). Journal of Medicinal Chemistry, 2003, 46, 2246-2249.	6.4	46
177	Rational Design, Synthesis, and Pharmacological Evaluation of 2-Azanorbornane-3-exo,5-endo-dicarboxylic Acid:Â A Novel Conformationally Restricted Glutamic Acid Analogue. Journal of Organic Chemistry, 2003, 68, 1489-1495.	3.2	36
178	Synthesis and Anticonvulsant Activity of Novel Bicyclic Acidic Amino Acids. Journal of Medicinal Chemistry, 2003, 46, 3102-3108.	6.4	26
179	Three Distinct Epitopes on the Extracellular Face of the Glucagon Receptor Determine Specificity for the Glucagon Amino Terminus. Journal of Biological Chemistry, 2003, 278, 28005-28010.	3.4	66
180	The Anticonvulsant Gabapentin (Neurontin) Does Not Act through Î³-Aminobutyric Acid-B Receptors. Molecular Pharmacology, 2002, 61, 1377-1384.	2.3	99

#	Article	IF	Citations
181	Novel 1-Hydroxyazole Bioisosteres of Glutamic Acid. Synthesis, Protolytic Properties, and Pharmacology. Journal of Medicinal Chemistry, 2002, 45, 19-31.	6.4	46
182	Selective Antagonists at Group I Metabotropic Glutamate Receptors:â€‰ Synthesis and Molecular Pharmacology of 4-Aryl-3-isoxazolol Amino Acids. Journal of Medicinal Chemistry, 2002, 45, 988-991.	6.4	7
183	Selective Agonists at Group II Metabotropic Glutamate Receptors:Â Synthesis, Stereochemistry, and Molecular Pharmacology of (S)- and (R)-2-Amino-4-(4-hydroxy[1,2,5]thiadiazol-3-yl)butyric Acid. Journal of Medicinal Chemistry, 2002, 45, 4240-4245.	6.4	15
184	The dance of the clams: twists and turns in the family C GPCR homodimer. Trends in Pharmacological Sciences, 2002, 23, 491-493.	8.7	32
185	Synthesis and pharmacology of 3-hydroxy-Î”2-isoxazoline-cyclopentane analogues of glutamic acid. Il Farmaco, 2002, 57, 889-895.	0.9	9
186	Glutamate receptor ligands: Synthesis, stereochemistry, and enantiopharmacology of methylated 2-aminoadipic acid analogs. Chirality, 2002, 14, 351-363.	2.6	5
187	Probing intermolecular protein-protein interactions in the calcium-sensing receptor homodimer using bioluminescence resonance energy transfer (BRET). FEBS Journal, 2002, 269, 5076-5087.	0.2	73
188	2-Amino-3-(3-hydroxy-1,2,5-thiadiazol-4-yl)propionic acid: resolution, absolute stereochemistry and enantiopharmacology at glutamate receptors. Bioorganic and Medicinal Chemistry, 2002, 10, 2259-2266.	3.0	25
189	Synthesis and Pharmacology of 3-Isoxazolol Amino Acids as Selective Antagonists at Group I Metabotropic Glutamic Acid Receptors. Journal of Medicinal Chemistry, 2001, 44, 1051-1059.	6.4	22
190	Synthesis and receptor binding affinity of new selective GluR5 ligands. Bioorganic and Medicinal Chemistry, 2001, 9, 875-879.	3.0	27
191	Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2001, 1518, 237-248.	2.4	73
192	Pharmacological characterization of homobaclofen on wild type and mutant GABAB1b receptors coexpressed with the GABAB2 receptor. European Journal of Pharmacology, 2001, 417, 177-180.	3.5	9
193	Construction of a High Affinity Zinc Binding Site in the Metabotropic Glutamate Receptor mGluR1. Journal of Biological Chemistry, 2001, 276, 10110-10118.	3.4	15
194	Ionotropic excitatory amino acid receptor ligands. Synthesis and pharmacology of a new amino acid AMPA antagonist. European Journal of Medicinal Chemistry, 2000, 35, 69-76.	5.5	17
195	The role of Arg78 in the metabotropic glutamate receptor mGlu1 for agonist binding and selectivity. European Journal of Pharmacology, 2000, 397, 247-253.	3.5	27
196	A new structural class of subtype-selective inhibitor of cloned excitatory amino acid transporter, EAAT2. European Journal of Pharmacology, 2000, 406, 41-44.	3.5	16
197	Functional Importance of the Ala116â€“Pro136 Region in the Calcium-sensing Receptor. Journal of Biological Chemistry, 2000, 275, 29547-29555.	3.4	57
198	Sequence and Expression Pattern of a Novel Human Orphan G-Protein-Coupled Receptor, GPRC5B, a Family C Receptor with a Short Amino-Terminal Domain. Genomics, 2000, 65, 121-128.	2.9	69

#	Article	IF	Citations
199	Ligands for Glutamate Receptors:â€‰ Design and Therapeutic Prospects. Journal of Medicinal Chemistry, 2000, 43, 2609-2645.	6.4	520
200	The Agonist-binding Domain of the Calcium-sensing Receptor Is Located at the Amino-terminal Domain. Journal of Biological Chemistry, 1999, 274, 18382-18386.	3.4	156
201	Agonists and Inverse Agonists for the Herpesvirus 8-encoded Constitutively Active Seven-transmembrane Oncogene Product, ORF-74. Journal of Biological Chemistry, 1999, 274, 956-961.	3.4	169
202	Synthesis and muscarinic receptor pharmacology of a series of 4,5,6,7-tetrahydroisothiazolo[4,5-c]pyridine bioisosteres of arecoline. Bioorganic and Medicinal Chemistry, 1999, 7, 795-809.	3.0	4
203	3-Pyrazolone analogues of the 3-isoxazolol metabotropic excitatory amino acid receptor agonist homo-AMPA. Synthesis and pharmacological testing. European Journal of Medicinal Chemistry, 1999, 34, 967-976.	5.5	18
204	Functional pharmacology of cloned heterodimeric GABAB receptors expressed in mammalian cells. British Journal of Pharmacology, 1999, 128, 1370-1374.	5.4	35
205	Synthesis and Enantiopharmacology of New AMPA-Kainate Receptor Agonists. Journal of Medicinal Chemistry, 1999, 42, 4099-4107.	6.4	42
206	Interaction of CPCCOEt with a chimeric mGlu1b and calcium sensing receptor. NeuroReport, 1999, 10, 3923-3925.	1.2	31
207	Pharmacology of (S)-homoquisqualic acid and (S)-2-amino-5-phosphonopentanoic acid [(S)-AP5] at cloned metabotropic glutamate receptors. British Journal of Pharmacology, 1998, 123, 269-274.	5.4	32
208	Synthesis and pharmacology of N-alkylated derivatives of the excitotoxin ibotenic acid. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 1563-1568.	2.2	6
209	Synthesis and Pharmacology of a New AMPAâ^'Kainate Receptor Agonist with Potent Convulsant Activity. Journal of Medicinal Chemistry, 1998, 41, 3759-3762.	6.4	11
210	Excitatory Amino Acid Receptor Ligands:Â Resolution, Absolute Stereochemistry, and Enantiopharmacology of 2-Amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic Acid. Journal of Medicinal Chemistry, 1998, 41, 930-939.	6.4	33
211	Molecular pharmacology of homologues of ibotenic acid at cloned metabotropic glutamic acid receptors. European Journal of Pharmacology, 1998, 350, 311-316.	3.5	40
212	(S)-Homo-AMPA, a Specific Agonist at the mGlu6 Subtype of Metabotropic Glutamic Acid Receptors. Journal of Medicinal Chemistry, 1997, 40, 3700-3705.	6.4	60
213	New analogues of ACPD with selective activity for group II metabotropic glutamate receptors. European Journal of Pharmacology, 1997, 332, 327-331.	3.5	8
214	Molecular pharmacology of 4-substituted glutamic acid analogues at ionotropic and metabotropic excitatory amino acid receptors. European Journal of Pharmacology, 1997, 335, R1-R3.	3.5	26
215	Pharmacology of muscarinic acetylcholine receptor subtypes (m1â€“m5): high throughput assays in mammalian cells. European Journal of Pharmacology, 1996, 295, 93-102.	3.5	106
216	Functional partial agonism at cloned human muscarinic acetylcholine receptors. European Journal of Pharmacology, 1996, 313, 145-150.	3.5	21

#	Article	IF	Citations
217	A New Highly Selective Metabotropic Excitatory Amino Acid Agonist:â€‰ 2-Amino-4-(3-hydroxy-5-methylisoxazol-4-yl)butyric Acid. Journal of Medicinal Chemistry, 1996, 39, 3188-3194.	6.4	74
218	Design of excitatory amino acid receptor agonists, partial agonists and antagonists: ibotenic acid as a key lead structure. European Journal of Medicinal Chemistry, 1996, 31, 515-537.	5.5	60
219	Structure of a G-protein-coupling Domain of a Muscarinic Receptor Predicted by Random Saturation Mutagenesis. Journal of Biological Chemistry, 1996, 271, 3058-3065.	3.4	63
220	High Throughput Assays of Cloned Adrenergic, Muscarinic, Neurokinin, and Neurotrophin Receptors in Living Mammalian Cells. Basic and Clinical Pharmacology and Toxicology, 1995, 76, 308-311.	0.0	25
221	Constitutive activation of muscarinic receptors by the G-protein Gq. FEBS Letters, 1995, 363, 261-263.	2.8	69